Showing papers by "David J. Hosking published in 2003"
TL;DR: It is demonstrated that the effects of risedronate over 3 years on vertebral fracture and BMD are maintained with a further 2 years of treatment, as well as rapid and significant decreases in markers of bone turnover observed in the first 3 years were similarly maintained in the next 2 Years of treatment.
264 citations
TL;DR: Tolerability was generally similar between ALN, RIS and PBO, and the incidence of upper GIAEs causing discontinuation and oesophageal AEs was similar in the ALN and RIS groups.
Abstract: SUMMARYObjective: To compare the effects of alendronate (ALN) 70mg once weekly (OW) and risedronate (RIS) 5mg daily between-meal dosing on biochemical markers of bone turnover and bone mineral density (BMD) in postmenopausal women with osteoporosis.Research design and methods: This was a 3-month, randomised, double-blind, placebo-controlled study with a double-blind extension to 12 months. The study enrolled 549 postmenopausal women (ALN 219, RIS 222 and placebo (PBO) 108) who were >60 years of age at outpatient centres.Main outcome measures: The primary endpoint was reduction in urine N-telopeptides of type 1 collagen (NTx) corrected for creatinine level at 3 months. Secondary parameters included change in BMD at the spine and hip at 6 and 12 months, NTx at 1,6 and 12 months, and serum bone-specific alkaline phosphatase (BSAP) at 1, 3, 6 and 12 months. Adverse experiences (AEs) were recorded throughout the study for an assessment of treatment safety profiles and tolerability.Results: Over 3 months, ALN p...
92 citations
TL;DR: There was a good correlation between changes in BMD at all sites and no significant difference in the slope of these correlations between the pregnant and control groups and there was a small and statistically nonsignificant decline during pregnancy.
78 citations
TL;DR: The optimal T-score for pDXA from ROC analysis was -1.7 and for QUS was -2.4, similar to the manufacturer's recommendations.
33 citations
TL;DR: Medical Management of Hypercalcemia S. H. Ralston, R. J. Hosking, J. S. Iqbal, E. McCloskey, D. Gallagher, S. Fraser, and S10 2SJ.
Abstract: Medical Management of Hypercalcemia S. H. Ralston, R. Coleman, W. D. Fraser, S. J. Gallagher, D. J. Hosking, J. S. Iqbal, E. McCloskey, D. Sampson Department of Medicine & Bone Metabolism, University of Aberdeen, AB25 2ZD, UK Department of Hematology, Hammersmith Hospital, London, W12 ONN, UK Department of Medicine, University of Sheffield, Sheffield, S10 2RX, UK Department of Medical Oncology, University of Sheffield, Sheffield, S10 2SJ, UK Consultant Physician, Southern General Hospital Glasgow, Glasgow, G51 4TF, UK Department of Mineral Metabolism, Nottingham City Hospital, Nottingham, NG5 1PB, UK Department of Biochemical Medicine, Leicester Royal Infirmary, Leicester, LE1 5WW, UK Department of Clinical Chemistry, University of Liverpool, Liverpool, L69 3GA, UK
32 citations
TL;DR: This study illustrates the use of serum-based bone turnover markers to assess turnover during normal pregnancy, a time when ionizing radiation cannot be used to assess bone turnover.
Abstract: BACKGROUND Maternal calcium homeostasis adapts during pregnancy to provide for the needs of the growing fetal skeleton. Wide selections of bone turnover markers are currently available to assess the changes taking place; here, data are presented on two serum-based markers. METHODS The use of serum-based biochemical bone turnover markers during pregnancy was assessed in a cohort of 41 women recruited prior to conception. Serum N-terminal extension peptide of procollagen (P1NP) was used to monitor bone formation and serum beta-crosslaps (S-CTX) used to assess resorption. Blood samples were measured at five time points from a pre-conceptual baseline, through pregnancy, to the final sample, which was taken within 1 week of delivery. RESULTS An initial decrease from the baseline in both P1NP and S-CTX was observed at 12 weeks; however, it is suggested that this may be due to the haemodilutional effect of pregnancy rather than a true change in bone turnover. Significant increases from the baseline of both analytes were observed by 36 weeks (P1NP, P = 0.013; S-CTX, P = 0.002), when the calcium demands of the fetus are greatest. CONCLUSIONS This study illustrates the use of serum-based bone turnover markers to assess turnover during normal pregnancy, a time when ionizing radiation cannot be used to assess bone turnover.
23 citations
3 citations